Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mechanisms underlying status epilepticus.

Katherine H Noe1, Edward M Manno

  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring COVID-19 census burdens by US hospital characteristics: Implications of quality reporting at rural and critical access hospitals.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association·2024
Same author

Society of Critical Care Medicine Clinical Practice Guidelines for Rapid Sequence Intubation in the Critically Ill Adult Patient: Executive Summary.

Critical care medicine·2023
Same author

Society of Critical Care Medicine Clinical Practice Guidelines for Rapid Sequence Intubation in the Critically Ill Adult Patient.

Critical care medicine·2023
Same author

A Journey Toward Gender Equity in Medicine.

Mayo Clinic proceedings·2023
Same author

A Multisite Assessment of Inpatient Safety Event Rates During the Coronavirus Disease 2019 Pandemic.

Mayo Clinic proceedings. Innovations, quality & outcomes·2023
Same author

Subclinical seizures on stereotactic EEG: characteristics and prognostic value.

Seizure·2022
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Status epilepticus involves prolonged seizures due to failed inhibition, primarily involving gamma-aminobutyric acid (GABA) pathways. Glutamate-targeting drugs show promise for treating seizures and preventing neuronal damage.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Status epilepticus (SE) presents significant mortality and morbidity.
  • SE involves prolonged or recurrent seizure activity.
  • Cellular mechanisms include failure of inhibitory pathways and activation of excitatory feedback loops.

Purpose of the Study:

  • To elucidate the cellular mechanisms underlying status epilepticus.
  • To explore the implications of these mechanisms for pharmacologic management.
  • To evaluate the potential of novel therapeutic agents.

Main Methods:

  • Analysis of inhibitory (GABAergic) and excitatory (glutamatergic) pathways in SE.
  • Review of current pharmacologic approaches and their efficacy.
  • Assessment of emerging therapeutic strategies targeting glutamate.

Related Experiment Videos

Main Results:

  • SE is characterized by a decline in gamma-aminobutyric acid (GABA)ergic function.
  • Excitatory glutamate pathways contribute to neuronal cell death in SE.
  • Current GABA(A) receptor-targeting agents lose effectiveness with prolonged SE duration.

Conclusions:

  • Pharmacologic management of SE requires addressing both GABAergic and glutamatergic systems.
  • Glutamate-inhibiting agents demonstrate potential for SE treatment and neuroprotection.
  • Understanding cellular pathways is crucial for developing effective SE therapies.